



Supporting Information

for

Synthesis and biological evaluation of new brassinosteroid analogs with C-22 benzoate function

María Núñez, Camila Escobar, Mario Párraga, Mauricio Soto, Luis Espinoza-Catalán, Katy Díaz and Andrés F. Olea

Beilstein J. Org. Chem. **2026**, 22, 753–762. [doi:10.3762/bjoc.22.57](https://doi.org/10.3762/bjoc.22.57)

NMR spectra of compounds, biological bioassays and protein–ligand interactions (molecular docking)

Table of contents

	pag.
Figure S1. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (23).	S8
Figure S2. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (23).	S8
Figure S3. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (23).	S9
Figure S4. ^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (23).	S9
Figure S5. ^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (23).	S10
Figure S6. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (24).	S10
Figure S7. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (24).	S11
Figure S8. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (24).	S11
Figure S9. ^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (24).	S12
Figure S10. ^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (24).	S12
Figure S11. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).	S13

Figure S12.	^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).	S13
Figure S13.	^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).	S14
Figure S14.	^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).	S14
Figure S15.	^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).	S15
Figure S16.	^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (26).	S15
Figure S17.	^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (26).	S16
Figure S18.	^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (26).	S16
Figure S19.	^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (26).	S17
Figure S20.	^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (26).	S17
Figure S21.	^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).	S18
Figure S22.	^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).	S18
Figure S23.	^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).	S19

Figure S24.	^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).	S19
Figure S25.	^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).	S20
Figure S26.	^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (28).	S20
Figure S27.	^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (28).	S21
Figure S28.	^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (28).	S21
Figure S29.	^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (28).	S22
Figure S30.	^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (28).	S22
Figure S31.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S23
Figure S32.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S23
Figure S33.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S24
Figure S34.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S24
Figure S35.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S25

Figure S36.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (17).	S25
Figure S37.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S26
Figure S38.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S26
Figure S39.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S27
Figure S40.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S27
Figure S41.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S28
Figure S42.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (18).	S28
Figure S43.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S29
Figure S44.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S29
Figure S45.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S30
Figure S46.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S30
Figure S47.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S31

Figure S48.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (19).	S31
Figure S49.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S32
Figure S50.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S32
Figure S51.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S33
Figure S52.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S33
Figure S53.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S34
Figure S54.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (20).	S34
Figure S55.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S35
Figure S56.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S35
Figure S57.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S36
Figure S58.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S36
Figure S59.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S37

Figure S60.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (21).	S37
Figure S61.	HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S38
Figure S62.	^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S38
Figure S63.	^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S39
Figure S64.	^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S39
Figure S65.	^1H - ^{13}C HSQC-ed. spectrum 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S40
Figure S66.	^1H - ^{13}C HMBC spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (22).	S40
Figure S67.	Analysis de Immunoblot showing dephosphorylation of BES1 after treatment with active compound 12 and 19 . WB: Western Blot; dBES1: dominant Brassinosteroid-Insensitive 1 Suppressor 1; DMSO: Dimethyl sulfoxide; kDa: Kilodalton. Representative images are shown. dBES1, dephosphorylated BES1.....	S41
Figure S68	BES1 phosphorylation status tested by immunoblot with α -BES1 antibody in roots of <i>Arabidopsis thaliana</i> ecotype Col-0 6-day-old seedlings after analogues of BR treatment. Tubulin detected with α -tubulin antibody was used as a loading control. The graph shows the percentage of dephosphorylated BES1 relative to total BES1 detected in wild-type <i>Arabidopsis</i> ecotype (Col-0) treated with brassinolide (1) after 6 days.....	S41

Figure S69.	Protein–ligand interactions with a) compound 12 b) compound 14 ; c) compound 16a , d) compound 17 , e) compound 18 , f) compound 19 , g) compound 20 , h) compound 21 and i) compound 22 . Hydrogen bonds are represented in green segmented lines. π – π stacking are represented in dark pink segmented lines. Hydrophobic interactions are represented in pink segmented lines. Visualization of the docked poses was performed using Discovery Studio Visualizer (BIOVIA, San Diego, CA, USA).	S46
Table S1.	Rice lamina assays using the second leaf lamina joints (angle opening, degrees) of excised leaf segments treated with BRs analogs (1 , 12 , 14 and 17–22) at different concentrations. Brassinolide was used as positive control at the same concentrations.	S47
Table S2.	Docked compounds–heterodimer protein contacts of synthetic analogs (12–22).	S48




Figure S1. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (**23**).




Figure S2. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (**23**).




Figure S3. ^{13}C -DEPT 135 NMR spectrum of 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (**23**).



Figure S4. ^1H - ^{13}C HSQC-ed. spectrum 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (**23**).




Figure S5. ^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methylbenzoate (**23**).




Figure S6. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (**24**).




Figure S7. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (**24**).




Figure S8. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (**24**).




Figure S9. ^1H - ^{13}C HSQC-ed. spectrum 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (**24**).



Figure S10. ^1H - ^{13}C HMBC spectrum of 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-methoxybenzoate (**24**).




Figure S11. ¹H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).




Figure S12. ¹³C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (25).




Figure S13. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (**25**).




Figure S14. ^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (**25**).




Figure S15. ^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-chlorobenzoate (**25**).




Figure S16. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (**26**).




Figure S17. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (**26**).




Figure S18. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (**26**).




Figure S19. ^1H - ^{13}C HSQC-ed. spectrum 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (**26**).



Figure S20. ^1H - ^{13}C HMBC spectrum of 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-bromobenzoate (**26**).




Figure S21. ¹H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).




Figure S22. ¹³C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (27).




Figure S23. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (**27**).




Figure S24. ^1H - ^{13}C HSQC-ed. spectrum 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodinebenzoate (**27**).




Figure S25. ^1H - ^{13}C HMBC spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-iodobenzoate (**27**).




Figure S26. ^1H NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (**28**).




Figure S27. ^{13}C NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (**28**).




Figure S28. ^{13}C -DEPT 135 NMR spectrum of 5 α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (**28**).




Figure S29. ^1H - ^{13}C HSQC-ed. spectrum 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (**28**).




Figure S30. ^1H - ^{13}C HMBC spectrum of 5α -cholan-6-oxo-2-ene-23,24-dinor-22-yl 4-cyanobenzoate (**28**).




Figure S31. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S32. ^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S33. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S34. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S35. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S36. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo-23,24-dinor-22-yl 4-methylbenzoate (**17**).




Figure S37. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).




Figure S38. ¹H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).




Figure S39. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).




Figure S40. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).



Figure S41. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).




Figure S42. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo-23,24-dinor-22-yl 4-methoxybenzoate (**18**).




Figure S43. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (**19**).




Figure S44. ^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (**19**).




Figure S45. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (**19**).




Figure S46. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-chlorobenzoate (**19**).




Figure S47. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-chlorobenzoate (**19**).




Figure S48. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-chlorobenzoate (**19**).




Figure S49. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (**20**).




Figure S50. ¹H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (**20**).




Figure S51. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (**20**).




Figure S52. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-bromobenzoate (**20**).




Figure S53. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-bromobenzoate (**20**).




Figure S54. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-bromobenzoate (**20**).




Figure S55. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (**21**).




Figure S56. ^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (**21**).




Figure S57. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (**21**).




Figure S58. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-iodobenzoate (**21**).




Figure S59. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-iodobenzoate (**21**).



Figure S60. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-iodobenzoate (**21**).




Figure S61. HRMS spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (**22**).




Figure S62. ^1H NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (**22**).




Figure S63. ^{13}C NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (**22**).




Figure S64. ^{13}C -DEPT 135 NMR spectrum of 2 α ,3 α -dihydroxy-5 α -cholan-6-oxo-23,24-dinor-22-yl 4-cyanobenzoate (**22**).




Figure S65. ^1H - ^{13}C HSQC-ed. spectrum $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-cyanobenzoate (**22**).




Figure S66. ^1H - ^{13}C HMBC spectrum of $2\alpha,3\alpha$ -dihydroxy- 5α -cholan-6-oxo- $23,24$ -dior- 22 -yl 4-cyanobenzoate (**22**).



Figure S67. Representative Western blot analysis showing dephosphorylation of BES1 after treatment with active compound **12** and **19**. WB: Western blot; dBES1: dominant Brassinosteroid-Insensitive 1 Suppressor 1; DMSO: Dimethyl sulfoxide; kDa: Kilodalton. Representative images are shown. dBES1, dephosphorylated BES1.








Figure S68: BES1 phosphorylation status tested by immunoblot with α -BES1 antibody in roots of *Arabidopsis thaliana* ecotype Col-0 6-day-old seedlings after analogues of BR treatment. Tubulin detected with α -tubulin antibody was used as a loading control. The graph shows the percentage of dephosphorylated BES1 relative to total BES1 detected in wild-type *Arabidopsis* ecotype (Col-0) treated with brassinolide (**1**) after 6 days.


a) Compound 12




b) Compound 14




c) Compound 16a




d) Compound 17





e) Compound 18





f) Compound 19



g) Compound 20



h) Compound 21



i) Compound **22**




























Figure S69. Protein–ligand interactions with a) compound **12** b) compound **14**; c) compound **16a**, d) compound **17**, e) compound **18**, f) compound **19**, g) compound **20**, h) compound **21** and i) compound **22**. Hydrogen bonds are represented in green segmented lines. Π – π stacking are represented in dark pink segmented lines. Hydrophobic interactions are represented in pink segmented lines. Visualization of the docked poses was performed using Discovery Studio Visualizer (BIOVIA, San Diego, CA, USA).

Table S1: Rice lamina assays using the second leaf lamina joints (angle opening, degrees) of excised leaf segments treated with BRs analogs (**1**, **12**, **14** and **17–22**) at different concentrations. Brassinolide was used as positive control at the same concentrations.

Compounds	RLIT (angle opening, degrees)		
	1×10^{-8} M	1×10^{-7} M	1×10^{-6} M
 <p>1</p>			
 <p>12</p>			
 <p>17</p>			
 <p>18</p>			
 <p>19</p>			
 <p>14</p>			




Table S2. Docked compounds–heterodimer protein contacts of synthetic analogs (**12–22**).

Compound	Protein contacts	
	Hydrogen bonds	Non-polar interactions
12	Asn705 His61 Tyr642 Ser647	Ile706, Tyr599, Phe681, Met657, Trp564, Pro648, Ile682, Ile592, Phe60
14	His61 Tyr642 Ser647	Ile706, Tyr597, Trp564, Phe681, Ile682, Phe60, Tyr597, Tyr599, Pro648
16a	Asn705 His61	Trp564, Phe681, Ile682, Phe60, Tyr642, Phe60, Tyr597
17	Asn705 Ser647 Tyr642	Tyr597, Trp564, Met657, Ile682, Phe60, Phe681, Tyr642
18	Ser647 Asn705	Tyr597, Trp564, Met657, Ile682, Phe60, Phe681, Tyr642

	His61	
19	Ser647 Val62 Tyr597 His61 Asn705 Tyr642	Tyr599, Trp564, Ile682, Phe60, Phe681, Tyr642, Ile706, Ile540, Ile563, Pro648
20	Ser647 Val62 His61 Asn705	Tyr599, Trp564, Ile682, Phe60, Phe681, Tyr642, Ile706, Ile540, Ile563, Pro648
21	Ser647 Asn705 Tyr642 His61	Tyr599, Trp564, Ile682, Phe60, Phe681, Tyr642, Ile706, Met657, Tyr597
22	Ser647 Val62 His61	Tyr599, Trp564, Ile682, Pro648, Phe681, Ile706, Phe60